• Suspected malignancy in symptomatic individuals: Patients with clinical features or imaging findings raising concern for cancer.
• Inconclusive or unfeasible tissue biopsy: Situations where conventional biopsy has not provided clear diagnostic information or carries procedural risk.
• Assessment of possible metastatic disease: Evaluation of suspected recurrence or new primary tumour in individuals with prior cancer history.
• Difficult-to-access tumour sites: Organs where invasive biopsy may be technically challenging or associated with higher complication risk.
• Need for non-invasive diagnostic support: Additional molecular information to complement imaging, laboratory findings or clinical assessment.

Overview

Trublood® is a minimally invasive oncology test that analyses circulating tumour cells and tumour-associated nucleic acids obtained from a peripheral blood sample. These biomarkers are released into the bloodstream from active tumour sites and can provide insight into tumour presence and biological characteristics.

The test may support cancer diagnosis in symptomatic individuals, particularly where tissue biopsy results are inconclusive or when invasive sampling is not feasible. Detection and characterisation of circulating tumour-associated markers may help inform diagnostic clarification and guide subsequent clinical decision-making.

Results are interpreted alongside imaging findings, tumour localisation, clinical presentation and other laboratory investigations. Integrating blood-based tumour biomarker analysis within the wider diagnostic pathway may support more timely and individualised oncology assessment.

Practical

Specimen

Whole blood 

Container

• 1 x 2 ml SST tube (yellow colour cap) 
• 2 x EDTA tubes (purple colour cap)

Volume

17 mL

Patient preparation

The patient must not have received any form of cancer therapy (radiation / chemo-therapy / surgery / endocrine therapy etc.) at least 15 days prior to collection of sample.
The patient must not have received oral or IV corticosteroids at least 15 days prior to collection of sample.
Patient has no current febrile or any other acute inflammatory illness.
Patient does not have acute exacerbation or flare-up of an inflammatory condition requiring escalation in medical therapy at least 5 days prior to collection of sample.
Patient has not received blood transfusion / PET-CT / CT scan at least 5 days prior to collection of sample.
Patient is not positive for HIV / HBV / HCV.